Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.
about
Immune Infiltration and Prostate CancerAllogeneic tumor cell vaccines: the promise and limitations in clinical trialsPSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical modelsNew developments in the medical management of prostate cancer.Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumorCombining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effectsCancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer.A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer.Therapies in development for castrate-resistant prostate cancer.Prostate cancer as a model for tumour immunotherapy.Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.Castration-resistant prostate cancer: new science and therapeutic prospects.Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model.Update on prostate cancer vaccinesImmunotherapy of cancer in 2012.Role of vaccine therapy in cancer: biology and practiceTherapeutic prostate cancer vaccines: a review of the latest developmentsDNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignanciesImmunology and immunotherapy approaches for prostate cancer.Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overviewCancer vaccines: moving beyond current paradigms.Talabostat.Immunotherapy for metastatic prostate cancerNovel therapeutic strategies in development for prostate cancer.Prostate cancer: genes, environment, immunity and the use of immunotherapy.Paradigm shifts in cancer vaccine therapy.How to detour Treg cells in T cell-based antitumor immune therapy.Mast cell mediators in tolerance.Oncolytic measles virus strains as novel anticancer agents.Emerging drugs for prostate cancer.Immunotherapy for prostate cancer: an emerging treatment modality.Update: immunological strategies for prostate cancer.Horizon scanning for novel therapeutics for the treatment of prostate cancer.Recent developments in prostate cancer biomarker research: therapeutic implications.Vaccines as consolidation therapy for myeloid leukemia.Cytokine and endocrine signaling in prostate cancer.Blood cells and their use in active immunotherapy of prostate cancer.Cancer immunotherapy: a paradigm shift for prostate cancer treatment.Prostate cancer vaccines in clinical trials.Cancer immunotherapies, their safety and toxicity.
P2860
Q26798412-A3203D38-238A-4FAF-B412-0A34FF6847FDQ26852333-369A625A-611F-445A-8B68-017DC5E81DA9Q27339832-0CF4EA08-908A-46A0-B9D5-151F13E4CD75Q33566738-BE4EE5BF-5DCA-4E5D-8C52-B29DB80F253AQ34000082-E01BC295-B199-4D35-8A12-E10F5A58A711Q34013869-62F1E1F2-7DA8-49E0-94F8-9C0B09A55D39Q34283691-CBEE23EF-F14A-4BE7-9246-81DA637B0487Q34315863-D4076B0A-97DF-4715-BC58-7398EDCCED83Q34588402-1259A789-0215-4F69-8EC1-91535C9B7B07Q34856875-75B55AAD-2B9D-4CA3-80EE-E4D04F6484A7Q34887495-F50028DD-266B-4D3A-857C-CD8FF8556F9EQ35076264-9EF7D55C-1313-498E-9D7E-8588EFF0D2A7Q35562729-BFA8A425-CD25-40D3-A80A-373EFD3C87DAQ36169608-44E6CD8C-4A82-4F53-B63C-D9AF0A96DC21Q36243536-9B283E18-7B42-47C5-9B22-10A157D7F674Q36256420-8A6DDF7C-37D7-4A38-8D23-D79535FA29E0Q36365743-1C8CF4F2-91FB-473F-8CA1-40F49119D87EQ36544893-621E6061-809F-4607-A8C3-2B43C6B81BA5Q36786512-29543BB0-11B6-4D43-838C-471E111495A4Q36806906-22AAF7DA-BA85-456F-86E0-89E3F3E91415Q36868126-C86DC564-D729-4561-AB8F-E1172610BBF4Q36916883-29C83BAE-0377-4998-8B16-EEB11677486CQ36949548-324B2027-1D4A-47B4-BFC8-BC9CB5C67427Q37038977-D8ECFC48-5B2F-4E18-A558-816102DDB07CQ37087947-80FB6562-C448-4632-BF21-C3704F4F4D59Q37122893-674C733A-B986-4886-AA02-D821C9B7DEF4Q37169964-75C877D9-3DED-41E2-BD33-553CA4BBBF3FQ37257141-3672BE93-B751-4CDD-8478-B8D090B4B38FQ37261017-4874322A-86A0-4482-B521-4B5AD03B75D5Q37570555-97406958-1B37-4988-887D-B54D73C90F5FQ37691634-30685964-0246-49D4-B1CE-2AFDA59C232DQ37738797-E87B0108-2B3A-42ED-A1A4-BC14AE88E23CQ37792060-889F0026-E53A-4E31-A29F-BE62217ADF5CQ37827186-9DBC6C4F-E30F-4633-B308-DBA8E82AA7CEQ37842342-8A6895A8-9AAC-44BB-AB61-5C86D870EF00Q37920776-0B4F8E3D-95E8-4FC1-BA1E-63855C0A78E0Q37988722-9D9F1105-A61D-42B6-AB83-6A4BB5407F0AQ38013964-7BDDDA4C-9D17-44C3-A4E5-330B20FE536AQ38036690-9B9F81D7-B8C2-47B5-ADCD-58C7F58C8985Q38106230-C148907B-7542-4243-A711-4F0DD73085FA
P2860
Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Granulocyte-macrophage colony- ...... X vaccine for prostate cancer.
@ast
Granulocyte-macrophage colony- ...... X vaccine for prostate cancer.
@en
type
label
Granulocyte-macrophage colony- ...... X vaccine for prostate cancer.
@ast
Granulocyte-macrophage colony- ...... X vaccine for prostate cancer.
@en
prefLabel
Granulocyte-macrophage colony- ...... X vaccine for prostate cancer.
@ast
Granulocyte-macrophage colony- ...... X vaccine for prostate cancer.
@en
P1433
P1476
Granulocyte-macrophage colony- ...... X vaccine for prostate cancer.
@en
P2093
Jonathan W Simons
Natalie Sacks
P304
P356
10.1016/J.UROLONC.2005.08.021
P577
2006-09-01T00:00:00Z